<SUBMISSION>
<ACCESSION-NUMBER>0001144204-18-025777
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20180507
<ITEMS>1.02
<ITEMS>2.01
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20180507
<DATE-OF-FILING-DATE-CHANGE>20180507
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>Alliqua BioMedical, Inc.
<CIK>0001054274
<ASSIGNED-SIC>3841
<IRS-NUMBER>582349413
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-36278
<FILM-NUMBER>18812300
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1010 STONY HILL ROAD
<STREET2>SUITE 200
<CITY>YARDLEY
<STATE>PA
<ZIP>19067
<PHONE>215-702-8550
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1010 STONY HILL ROAD
<STREET2>SUITE 200
<CITY>YARDLEY
<STATE>PA
<ZIP>19067
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>Alliqua, Inc.
<DATE-CHANGED>20101222
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>HEPALIFE TECHNOLOGIES INC
<DATE-CHANGED>20030529
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ZETA CORP
<DATE-CHANGED>20030219
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv493310_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
May 7, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Alliqua BioMedical, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; text-align: center; border-bottom: Black 1pt solid">Delaware</TD>
    <TD STYLE="width: 5%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: center; border-bottom: Black 1pt solid">001-36278</TD>
    <TD STYLE="width: 5%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: center; border-bottom: Black 1pt solid">58-2349413</TD></TR>
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="text-align: center">(State or other jurisdiction<BR> of incorporation)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="text-align: center">(IRS Employer<BR> Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 65%; text-align: center; border-bottom: Black 1pt solid">2150 Cabot Boulevard West, Suite B, Langhorne, Pennsylvania</TD>
    <TD STYLE="vertical-align: top; width: 5%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 30%; text-align: center; border-bottom: Black 1pt solid">19047</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">(Zip Code)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (215) 702-8550</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">1010 Stony Hill Road Suite 200 Yardley, Pennsylvania, 19067</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Former name or former address, if changed since last report)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 2pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: -13.5pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: -13.5pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;Pre-commencement communications
pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Emerging growth company
<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 1.02</B></TD><TD><B>Termination of a&nbsp;Material Definitive Agreement.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 7, 2018, in connection with the completion
of the Asset Sale (as defined below), Alliqua BioMedical, Inc. (the &ldquo;Company&rdquo;) terminated its Credit Agreement and
Guaranty (the &ldquo;Credit Agreement&rdquo;), dated as of May 29, 2015, as amended, by and among the Company, AquaMed Technologies,
Inc., a wholly owned subsidiary of the Company (&ldquo;Guarantor&rdquo;), and Perceptive Credit Holdings LP (&ldquo;Perceptive&rdquo;).
The Credit Agreement provided for a senior secured term loan in a single borrowing to the Company in the principal amount of approximately
$15.5 million. The full unpaid principal amount of the term loan was to mature on May 29, 2019. In connection with the termination
of the Credit Agreement, the Company also paid to Perceptive an exit fee in the amount of $242,695.60 and a prepayment premium
of $242,695.60.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company also terminated the related
Pledge and Security Agreement, dated as of May 29, 2015, by and among the Company, Guarantor and Perceptive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 2.01</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Completion of Acquisition
or Disposition of Assets.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 7, 2018, the Company completed the
sale (the &ldquo;Asset Sale&rdquo;) of substantially all of its assets to Celularity, Inc. (the &ldquo;Buyer&rdquo;), including
certain assets comprising its MIST, Biovance and Interfyl product lines (the &ldquo;Purchased Assets&rdquo;) pursuant to the terms
of the Asset Purchase Agreement, dated January 5, 2018 (the &ldquo;Asset Purchase Agreement&rdquo;) with Buyer. As consideration
for the Purchased Assets, Buyer paid a purchase price of $29 million in cash. No debt or significant liabilities were assumed by
Buyer in the Asset Sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Asset Purchase Agreement,
the Company retained certain specified assets, including, among other things, cash, accounts receivable and its hydrogel contract
manufacturing business, including its SilverSeal and Hydress product lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Asset Purchase
Agreement and the Asset Sale does not purport to be complete and is qualified in its entirety by reference to the Asset Purchase
Agreement which was filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) as Exhibit 2.1 to the Company&rsquo;s
Current Report on Form 8-K filed with the SEC on January 5, 2018 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 8.01</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 7, 2018, the Company issued a press
release in which it announced that it completed the Asset Sale pursuant to the Asset Purchase Agreement. A copy of the press release
is attached to this Current Report on Form 8-K as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Financial Statements and
Exhibits.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD>Pro Forma Financial Information</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
unaudited pro forma consolidated financial information for the years ended December 31, 2017 and 2016 included in the Company&rsquo;s
definitive proxy statement filed with the SEC on March 30, 2018, beginning on page 65 is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD><FONT STYLE="font-size: 10pt">Exhibits</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 15%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 80%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1054274/000114420418001112/tv482784_ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2.1*</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1054274/000114420418001112/tv482784_ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Asset Purchase Agreement, dated January 5, 2018, between Alliqua BioMedical, Inc. and Celularity Inc. (incorporated by reference to Exhibit 2.1 to the Company&rsquo;s Current Report on Form 8-K filed on January 5, 2018).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><A HREF="tv493310_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><A HREF="tv493310_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release, dated May 7, 2018, issued by Alliqua BioMedical, Inc.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1054274/000114420418018056/tv488236-defm14a.htm#tUNFINI" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.2</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1054274/000114420418018056/tv488236-defm14a.htm#tUNFINI" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Unaudited pro forma financial information of the Company (incorporated by reference to the Company&rsquo;s definitive proxy statement filed on March 30, 2018).</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Schedules have been omitted pursuant to Item 601(b)(2) of
Regulation S-K. The Company agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule
upon request, subject to the Company&rsquo;s right to request confidential treatment of any requested schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>ALLIQUA BIOMEDICAL, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 47%">Dated: May 7, 2018</TD>
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 41%; border-bottom: Black 1pt solid">/s/ Joseph Warusz</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Name: Joseph Warusz<BR>Title: Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv493310_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">May 7, 2018</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="alqa_logo1.jpg"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.1pt"><B>Alliqua BioMedical, Inc. Announces Closing Asset
Sale to Celularity Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Alliqua to return capital to
shareholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>Alliqua Retains H.C. Wainwright
and Co. to evaluate strategic options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">LANGHORNE, Pa., May 07,
2018 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) (&ldquo;Alliqua&rdquo; or &ldquo;the Company&rdquo;), a provider of
advanced wound care products, today announced that it has completed its previously announced asset sale to Celularity Inc. of its
property, assets and rights relating to the Company&rsquo;s advanced biologic wound care business, UltraMist&reg; Therapy System
and other therapeutic ultrasound platform products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;We are excited about
the completion of the transaction, which will now allow Alliqua to focus on maximizing the value of its remaining assets&rdquo;,
said David Johnson, CEO of Alliqua.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Alliqua
intends to return capital back to its stockholders on a per share basis of between $1.40 per share to $1.80 per share in the
fourth quarter of 2018. In addition, Alliqua recently engaged H.C. Wainwright &amp; Co. to provide a range of advisory
services to the Company aimed to seek and evaluate strategic alternatives for Alliqua, including acquisition, merger,
strategic partnership or other strategic transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>About Alliqua
BioMedical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Alliqua can provide a custom
manufacturing solution to partners in the medical device; cosmetics; and OTC industry, utilizing its proprietary hydrogel technology.
Alliqua&rsquo;s electron beam production process, located at its 16,500 square foot GMP manufacturing facility in Langhorne, PA, allows
Alliqua to custom manufacture a wide variety of hydrogels. Alliqua&rsquo;s hydrogels can be customized for various transdermal applications
to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical
and cosmetic industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For additional information,
please visit http://www.alliqua.com. To receive future press releases via email, please visit https://ir.stockpr.com/alliqua/email-alerts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>About Celularity
Inc.:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Celularity, headquartered
in Warren, New Jersey, is a biotechnology company that has leading-edge technology and an associated intellectual property portfolio
that uniquely positions Celularity to harness the power of the placenta. Their asset portfolio consists of more than 800 granted
patents worldwide, as well as pre-clinical and clinical assets including CAR constructs for allogeneic CAR-T/NK products, and
commercial stage biosourcing and functional regeneration businesses. For more information, please visit www.celularity.com. Follow
Celularity on Social Media: @Celularity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Legal Notice
Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This release contains forward-looking
statements. Forward-looking statements are generally identifiable by the use of words like &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;believe,&rdquo; &ldquo;intend,&rdquo; or
&ldquo;project&rdquo; or the negative of these words or other variations on these words or comparable terminology. The reader is
cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and
uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company&rsquo;s
liquidity to pursue its complete business objectives; inadequate capital; the Company&rsquo;s ability to obtain reimbursement from third
party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of
a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological
obsolescence of the Company&rsquo;s products; technical problems with the Company&rsquo;s research and products; the Company&rsquo;s ability to expand
its business through strategic acquisitions; the Company&rsquo;s ability to integrate acquisitions and related businesses; price increases
for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other
factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our Annual Report
on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge
on the SEC&rsquo;s web site at http://www.sec.gov. We undertake no obligation to publicly update
or revise our forward-looking statements as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Investor Relations Alliqua:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Joe Warusz, Chief Financial Officer<BR>
ir@alliqua.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><IMG SRC="alqa_logo2.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Source: Alliqua BioMedical, Inc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>alqa_logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 alqa_logo1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 0$# 2(  A$! Q$!_\0
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I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>alqa_logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 alqa_logo2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  N )8# 2(  A$! Q$!_\0
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@F#X,L1>M=0S3PNR[2J$!>W;'7@45U&**GG9I[*'8_]D!

end
</TEXT>
</DOCUMENT>
</SUBMISSION>
